Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― ...
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III ...
For students in Calculus III. This post covers the essential ideas behind double and triple integrals — what they mean geometrically, how to set them up, and how to compute them. All material follows ...
TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that at ESCMID Global 2026, to be held from 17 ...
Under this contract, Inprentus will manufacture ultra-high-precision spherical diffraction gratings for a next-generation solar sounding rocket experiment. Inprentus’ unique curved grating technology ...
CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results